| CIP2A protein expression in high-grade, high-stage bladder cancer. | bladder, |
| CIP2A is overexpressed in osteosarcoma and regulates cell proliferation and invasion. | osteosarcoma, |
| Fusogenic-oligoarginine peptide-mediated delivery of siRNAs targeting the CIP2A oncogene into oral cancer cells. | liver, |
| p90/CIP2A mediates breast cancer cell proliferation and apoptosis. | breast, |
| CIP2A is an Oct4 target gene involved in head and neck squamous cell cancer oncogenicity and radioresistance | HNSC, |
| Fusogenic-oligoarginine peptide-mediated silencing of the CIP2A oncogene suppresses oral cancer tumor growth in vivo. | oral |
| Copy number increase of oncoprotein CIP2A is associated with poor patient survival in human head and neck squamous cell carcinoma. | HNSC, |
| CIP2A inhibits PP2A in human malignancies. | None |
| Data show that CIP2A expression can be systematically inhibited without severe consequences to normal mouse development and viability may have clinical relevance regarding targeting of oncogenic CIP2A for future cancer therapies. | None |
| Expression and biological role of CIP2A in human astrocytoma. | None |
| CIP2A is a novel anticancer target based on PP2A reactivation and inhibition of the oncogenic activity of its downstream effectors.[review] | None |
| CIP2A oncoprotein controls cell growth and autophagy through mTORC1 activation. | None |
| Oncogenic nexus of cancerous inhibitor of protein phosphatase 2A (CIP2A): an oncoprotein with many hands. | None |
| Studies indicate that oncoprotein CIP2A (KIAA1524) controls oncogenic cellular signals by suppressing protein phosphatase 2A (PP2A). | None |
| Oncoprotein CIP2A is stabilized via interaction with tumor suppressor PP2A/B56 | None |